These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. [New insights in the pathophysiology of preeclampsia and potential therapeutic implications]. Boulanger H; Flamant M Nephrol Ther; 2007 Dec; 3(7):437-48. PubMed ID: 18047998 [TBL] [Abstract][Full Text] [Related]
46. Update on the pathophysiological implications and clinical role of angiogenic factors in pregnancy. Llurba E; Crispi F; Verlohren S Fetal Diagn Ther; 2015; 37(2):81-92. PubMed ID: 25659427 [TBL] [Abstract][Full Text] [Related]
47. VEGF expression in the placenta from pregnancies complicated by hypertensive disorders. Sgambati E; Marini M; Zappoli Thyrion GD; Parretti E; Mello G; Orlando C; Simi L; Tricarico C; Gheri G; Brizzi E BJOG; 2004 Jun; 111(6):564-70. PubMed ID: 15198784 [TBL] [Abstract][Full Text] [Related]
48. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Maynard SE; Venkatesha S; Thadhani R; Karumanchi SA Pediatr Res; 2005 May; 57(5 Pt 2):1R-7R. PubMed ID: 15817508 [TBL] [Abstract][Full Text] [Related]
49. Placental overexpression of transforming growth factor-beta3 in the HELLP syndrome. Emanuelli M; Giannubilo SR; Landi B; Sartini D; Pierella F; Corradetti A; Tranquilli AL Gynecol Obstet Invest; 2008; 65(1):1-5. PubMed ID: 17671384 [TBL] [Abstract][Full Text] [Related]
50. Possible joint pathways of early pre-eclampsia and congenital heart defects via angiogenic imbalance and potential evidence for cardio-placental syndrome. Sliwa K; Mebazaa A Eur Heart J; 2014 Mar; 35(11):680-2. PubMed ID: 24302271 [No Abstract] [Full Text] [Related]
51. Circulating angiogenic factors and the risk of preeclampsia. Levine RJ; Maynard SE; Qian C; Lim KH; England LJ; Yu KF; Schisterman EF; Thadhani R; Sachs BP; Epstein FH; Sibai BM; Sukhatme VP; Karumanchi SA N Engl J Med; 2004 Feb; 350(7):672-83. PubMed ID: 14764923 [TBL] [Abstract][Full Text] [Related]
55. Modulation of the angiogenesis response through Ha-ras control, placenta growth factor, and angiopoietin expression in mouse skin carcinogenesis. Larcher F; Franco M; Bolontrade M; Rodriguez-Puebla M; Casanova L; Navarro M; Yancopoulos G; Jorcano JL; Conti CJ Mol Carcinog; 2003 Jun; 37(2):83-90. PubMed ID: 12766907 [TBL] [Abstract][Full Text] [Related]
56. The basic residues of placenta growth factor type 2 retrieve sequestered angiogenic factors into a soluble form: implications for tumor angiogenesis. Barillari G; Albonici L; Franzese O; Modesti A; Liberati F; Barillari P; Ensoli B; Manzari V; Santeusanio G Am J Pathol; 1998 May; 152(5):1161-6. PubMed ID: 9588884 [TBL] [Abstract][Full Text] [Related]
57. Pathogenesis of preeclampsia. Sircar M; Thadhani R; Karumanchi SA Curr Opin Nephrol Hypertens; 2015 Mar; 24(2):131-8. PubMed ID: 25636145 [TBL] [Abstract][Full Text] [Related]
59. Recent advances in understanding of preeclampsia. Bdolah Y; Karumanchi SA; Sachs BP Croat Med J; 2005 Oct; 46(5):728-36. PubMed ID: 16158464 [TBL] [Abstract][Full Text] [Related]
60. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin. Bujold E; Romero R; Chaiworapongsa T; Kim YM; Kim GJ; Kim MR; Espinoza J; Gonçalves LF; Edwin S; Mazor M J Matern Fetal Neonatal Med; 2005 Jul; 18(1):9-16. PubMed ID: 16105786 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]